Kornimate/medical-research-clean huggingface dataset:
psychological and physical distress and care needs in operable lung cancer patients receiving surgery

Conditions: Anxiety Postoperative; Patient Non-Compliance; Psychological Distress

Summary: the lung cancer is the most has the life minacity in all kinds of cancers, and it also remains the most common cause of cancer-related death in the world. the group of lung cancer patients are suffer from huge disease impact that came from high mortality. not only the course of treatment that patients has been diagnosis through operation is more faster, but also those who could be capable of operated are stabilized to keep follow-up at out-patient clinic. but in the next following five years after operation, they may take different dysfunctional level or some kinds of symptom distress. the effect has a great influence on those patients that have to face extended emotional impact, symptom distress and life style change. in addition, most of them concern about recurrent all the time in the remission. these situation needs us to place importance on it. the purposes of this study are to investigate psychological and physical distress and care needs in operable lung cancer patients receiving surgery. this survey includes two parts of physical and mental condition. first, the investigators are scoring their symptom severity and quality of life to check physical condition. seconded, the mental condition will use validated questionnaires to realize the relationship of anxiety, depression, uncertainty, fear of recurrence, self-efficacy and needs. final, compare all of the data to patients' needs. this study is a cross-sectional designs with convenience sampling that conform to the investigators recruited requirements. the investigators will recruit from the clinic of thoracic surgery in one medical center in taipei and take five structured requirements. and the investigators are going to collect data from january, 2011 to december, 2012. also expect results are lung cancer outpatients after surgery that more physical dysfunction or more depress of mental condition, it will lead patients' needs increased or significant difference. in conclusion, this study analyzes their needs in the remission that consequences can be medical professionals' reference material.

inclusion criteria: lung cancer patients after surgery stage i, ii and iiia surgery for 3 months to 5 years over 20 years old exclusion criteria: lung cancer recurrence conscious unclear and do not know having cancer used to be treat (surgery, chemotherapy or radiotherapy) in 3 months. be uncomfortable or cooperate to fill the questionnaire.

Eligibility criteria:
inclusion criteria: * lung cancer patients after surgery * stage i, ii and iiia * surgery for 3 months to 5 years * over 20 years old exclusion criteria: * lung cancer recurrence * conscious unclear and do not know having cancer * used to be treat (surgery, chemotherapy or radiotherapy) in 3 months. * be uncomfortable or cooperate to fill the questionnaire.

Keywords: lung cancer symptom distress post-operation anxiety depression uncertainty fear of recurrence self-efficacy needs
integral physiological adaptations to carbohydrate periodization

Conditions: Sleepiness; Fatigue; Feeding Patterns; Daytime Sleepiness, Excessive

Summary: the purpose of this study is to examine the effect of long-term carbohydrate periodization protocols on sleep architecture, sleep quality, daytime sleepiness, physical performance, body composition, gut microbiome, and mirna in healthy trained individuals.

athletic populations have been particularly susceptible to sleep inadequacies, experience several sleep issues, and fall below the age-specific sleep recommendations. however, it is well demonstrated that exercise does not impair sleep by itself, and furthermore, acute post-exercise nutrition could elevate the exercise-induced sleep-optimizing effect, with further benefits for the next physical performance. in line with these findings, in a metanalysis of clinical trials, it was shown that pre-bed carbohydrate availability resulted in significant alterations in sleep architecture. it is of utmost importance to highlight that throughout this metanalysis, it was revealed that no long-term nutrition intervention for sleep optimization has been studied yet. these data raise the question of whether a long-term carbohydrate periodization protocol could optimize sleep and alter gut function in a way that athletic performance will be also enhanced. this would allow elucidating further potential interrelations and biological pathways underlying these adaptations.

Eligibility criteria:
inclusion criteria: * both sexes, age between 18 and 50 yrs old, regularly participating in sports activities. exclusion criteria: * any kind of history of major diseases or medication, excessive amounts of alcohol and caffeine consumption

Keywords: sleep carbohydrate periodization dietary intervention sports nutrition chrononutrition chronobiology gut microbiome mirna
compare the effects of single versus repeated intracoronary application of autologous bone marrow-derived mononuclear cells on mortality in patients with chronic post-infarction heart failure

Conditions: Heart Failure

Summary: single or repeated application of autologous bone marrow-derived stem cells to treat chronic post-infarction heart failure

improve mortality and morbidity in patients with symptomatic chronic post-infarction heart failure under full dose conventional medical and device treatment including resynchronization therapy, by single versus repeated intracoronary infusion of autologous bone marrow-derived mononuclear cells.

Eligibility criteria:
inclusion criteria: * previous myocardial infarction at least 3 months ago, open infarct vessel or bypass * left ventricular ejection fraction (lvef) ≤ 45% on echocardiography * stable chronic heart failure nyha class ii to iii under constant (4 weeks) evidence-based optimal medical treatment * age 18 - 80 years * written informed consent * women of childbearing age: negative pregnancy test; effective contraception for the first 8 months in the trial exclusion criteria: * non-ischemic cardiomyopathy * necessity for revascularization in other vessel than the infarct vessel at the time of study therapy * hemodynamic relevant severe valvular disease with indication for operative / interventional revision * heart failure with preserved ejection fraction (diastolic heart failure), lvef \> 45% * unstable angina * severe peripheral artery occlusive disease (≥ fontaine stadium iii) * active infection (c-reactive protein \> 10 mg/dl), chronic active hepatitis; any chronic inflammatory disease, hiv infection * neoplastic disease without documented remission in the last 5 years * stroke ≤ 3 months * impaired renal function (serum creatinine \> 2,5 mg/dl) at the time of study inclusion * relevant liver disease (got \> 2x upper normal limit, spontaneous inr \> 1,5). * diseases of hematopoetic system, anemia (hemoglobin \< 8.5 mg/dl), thrombocytopenia \< 100.000/µl) * splenomegaly * allergy or intolerance of clopidogrel, prasugrel, ticagrelor, heparin, bivalirudin * history of bleeding disorder * gastrointestinal bleeding ≤ 3 months * major surgery or trauma ≤ 3 months * uncontrolled hypertension * pregnancy, lactation period * mental retardation * previous cardiac cell therapy within last 12 months * participation in another clinical trial ≤ 30 days

Keywords: heart failure old myocardial infarction bone marrow-derived mononuclear cells chronic ischemic
utility of non-invasive carboxyhemoglobin and total hemoglobin measurement in the emergency department

Conditions: Carbon Monoxide Poisoning; Anemia

Summary: the purpose of this study is to determine the clinical utility of triage screening for anemia and carbon monoxide poisoning (cop) in the ed setting.this is a prospective, nonrandomized, multi-center study of the performance of simultaneous non-invasive testing for two common disorders (cop and anemia). we will determine the limits of agreement and performance characteristics of non-invasive carboxyhemoglobin (spco) and hemoglobin (sphb) values compared to standard blood tests for measurement of carboxyhemoglobin and hemoglobin, in the emergency department setting.


Eligibility criteria:
inclusion criteria: * age 1 year or older. * at least one digit has acceptable width as measured by study-provided digit gauge. * presenting to emergency department for any complaint. * potential for iv catheter and/or blood draw for cbc as standard of care. exclusion criteria: * patients unable to consent for any reason * patients with fingernail polish, discoloration or trauma to fingers
pilot study of fostamatinib disodium/r935788 for the treatment of adult refractory immune thrombocytopenic purpura (itp)

Conditions: Purpura, Thrombocytopenic, Idiopathic

Summary: the purpose of this study is to determine whether fostamatinib disodium is safe and effective in the treatment of adult refractory immune thrombocytopenic purpura (itp).

patients with chronic refractory itp are eligible for a 6- to 12-week therapeutic trial. after 24 months of treatment, patients who continue to demonstrate a sustained response, in the investigator's judgment, will be offered the opportunity to receive ongoing therapy.

Eligibility criteria:
inclusion criteria: * patients must be willing and able to give written informed consent by signing an irb-approved informed consent form prior to admission to this study. * patients may be male or female, between the ages of 18 75. men, if sexually active, must agree to use at least one medically acceptable form of birth control. women of childbearing potential must have a negative urine pregnancy test, and agree to use two independent methods of birth control, if sexually active. * patients must have a diagnosis of chronic refractory itp for at least 3 months. chronic refractory itp is defined as: 1. platelet count \< 30,000/mm3 consistently for 3 months (except for transient nonsustained responses to various therapeutic regimens). there must be at least three separate platelet counts (below 30,000/mm3) over this period, with at least one extending back to three months or more prior to patient entry into the study. 2. the following conditions will have been excluded either by history or appropriate laboratory investigation: hiv infection (see below), lymphoproliferative disorders, myelodysplasia, sle, drug-induced or alloimmune thrombocytopenia, or dysglobulinemias. 3. the patient must have tried at least two typical regimens for the treatment of itp (george et al., blood, 1996; practice guidelines, american society of hematology). at least 50% of the enrolled patients will not be known to be refractory to ivig. patients may or may not have been treated with ivig in the past. * subjects must test negative for hiv, hbv, and hcv by standard serologic tests within the previous six months. exclusion criteria: * patients who have a history or presence of substantial or clinically significant respiratory, gastrointestinal, renal, hepatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, dermatological, or other disorders that, in the investigator's opinion, could affect the conduct of the study or the absorption, metabolism or excretion of the study drug are excluded. specifically excluded are lymphoma/chronic lymphocytic leukemia, hepatitis, or hiv associated with itp. * patients who have a history of relevant drug hypersensitivity are excluded. * patients who have a history of substance abuse, drug addiction or alcoholism are excluded. * patients with the following laboratory abnormalities: a leukocyte count \ 1.5xuln are excluded.

Keywords: adult refractory immune thrombocytopenic purpura (itp)
a digital method for measurement of palatal asymmetry in twins

Conditions: Identity, Body; Palate; Deformity

Summary: the aim of the study is to evaluate the digital palatal model as a possible tool of human identification.

in this research, the investigators investigate the individual characteristics of the human upper and lower dentition and palate. the investigators use digital dentistry, record the data using an intraoral scanner, and store the extracted open source file format on a secure cloud-based server. data validation is repeated annually. by comparing the initial and control digital samples, the investigators draw conclusions about the usability of the extracted information. the aim of the study is to develop a method and data storage protocol that will allow the patient data to be used years or decades later to replace or restore lost information.

Eligibility criteria:
inclusion criteria: * monozygotic twins * same-sex dizygotic twins * opposite-sex dizygotic twins * triplets exclusion criteria: * marfan-syndrome * non-twins

Keywords: human identification palate morphology intraoral scanner digital dentistry
mixed natural prebiotic-fibers impact on stool frequency and fecal microbiota in constipated thai adults

Conditions: Constipation

Summary: mixed natural prebiotic-fibers impact on stool frequency and fecal microbiota in constipated thai adults: a randomized clinical trial.


Eligibility criteria:
inclusion criteria: * healthy adults with a body mass index (bmi) of 16.00 to 29.99 kg/m2 * self-reported constipation according to the rome iv criteria exclusion criteria: * pregnancy * crohn's disease or any other inflammatory bowel disease * pelvic floor dyssynergia * have congenital diseases such as liver disease, diabetes, and thyroid dysfunction. hypercalcemia neurological disease * drink alcohol or smoke regularly. * during the past 1 month or while in the project, have received antibiotics, steroids, nsaids, blood pressure-lowering drugs, antidepressants, anticonvulsants, or parkinson's disease medications * history of food allergy to haruna's ingredients * there has been a change in body weight (increase or decrease of 5 kilograms over a period of 6 months). * during the past 2 weeks or while in the project, have received probiotics or other prebiotics
ventilatory efficiency in critically ill covid-19 patients

Conditions: ARDS

Summary: the new severe acute respiratory syndrome coronavirus 2019 (sars-cov-2) causes the illness named covid-19, which is primarily characterized by pneumonia. as of 27 december, there have been over 79.2 million cases and over 1.7 million deaths reported since the start of the pandemic. in many cases, pneumonia evolves to acute respiratory distress syndrome (ards) with the need for mechanical ventilation and patient admission to intensive care unit, determining a marked increase in the need for intensive care beds worldwide. pulmonary involvement causes predominantly hypoxemic respiratory failure. although covid-19 pneumonia often falls within the diagnostic criteria of ards, it differs from it for some peculiar pathophysiological characteristics. in particular, patients with ards secondary to covid-19 often have the compliance of the respiratory system within the normal range. a significant role in the pathophysiology of hypoxemia seems to depend on vascular alterations such as altered pulmonary vascular self-regulation, pulmonary capillary leakage, and microvascular thrombosis in a complex process known as "immunothrombosis". all together they act by altering the relationship between ventilation and perfusion and increasing the dead space, which ultimately results in impaired efficiency of the pulmonary ventilation. among the various markers associated with the prognosis of patients with covid-19, d-dimer is linked to both the inflammatory state and thrombotic phenomena and could help to identify patients at greater risk of developing early ventilation-perfusion changes. this study aims at measuring the ventilatory efficiency, assessed by ventilatory ratio, in critically ill, mechanically ventilated, covid-19 patients and its correlation with plasma d-dimer and quasi-static respiratory compliance.


Eligibility criteria:
inclusion criteria: all of the following: * confirmed sars-cov-2 infection by rt-pcr on a nasopharyngeal swab * severe hypoxemia due to covid-19 who meets the diagnostic criteria of ards (berlin's definition) * invasive mechanical ventilation * patients receiving neuromuscular blocking drugs exclusion criteria: * history of preexisting severe hypoxemia (i.e. primary pulmonary hypertension, copd in therapy with o2 supplementation, pulmonary fibrosis, etc.) * severe haemodynamic instability defined as: * mean arterial pressure \< 65 mmhg despite the infusion of norepinephrine, or epinephrine, or dobutamine, or levosimendan * severe left ventricular dysfunction with ejection fraction \<20% * right ventricular failure due to pulmonary embolism

Keywords: ventilatory ratio mechanical ventilation ards covid-19 critical illness dead-space
association between local cerebral oxygenation monitoring and postoperative stroke in carotid endarterectomy

Conditions: Carotid Endarterectomy; Cerebral Autoregulation

Summary: carotid endarterectomy (cea) is used to treat symptomatic extracranial internal carotid artery stenosis. the occult stroke of cea patients evaluated by magnetic resonance imaging 3 days after operation was as high as 17%. cerebral blood flow autoregulation (ca) is the ability of the brain to maintain the relative stability of cerebral blood flow, and cerebral oxygen index (cox) can be used to reflect ca. a negative value of cerebral oxygen index or a value near zero indicates that ca is complete, and cerebral oxygen index close to 1 indicates that ca has lost its ability. in theory, real-time monitoring of ca function by cerebral oxygen index and individualized management strategy with this goal can potentially reduce perioperative ischemic brain injury. the purpose of this study is to explore the influence of the management strategy of monitoring ca function based on regional cerebral oxygen saturation on the postoperative neurological complications of cea patients.


Eligibility criteria:
inclusion criteria: * patients scheduled for elective carotid endarterectomy * asa ⅱ or ⅲ * aged 18-80 years old exclusion criteria: * preoperative moderate and severe cognitive impairment * preoperative psychotropic medication history within one year * history of neurosurgery * have speech or language impairments
post-authorization safety study in north america to monitor pregnancy and infant outcomes following administration of dupilumab during planned or unexpected pregnancy

Conditions: Atopic Dermatitis (AD); Asthma

Summary: the objective is to evaluate the potential effect of exposure to dupilumab in pregnancy compared to the primary comparison group of disease-matched pregnant women who are not exposed to dupilumab, and the secondary comparison group of healthy pregnant women. the primary outcome of the study is major structural defects, and the secondary outcomes of the study are spontaneous abortion/miscarriage, stillbirth, elective termination/abortion, premature delivery, small for gestational age, pattern of 3 or more minor structural defects, postnatal growth of live born children to 1 year of age, postnatal serious or opportunistic infections in live born children to 1 year of age, and hospitalizations in live children up to 1 year of age.


Eligibility criteria:
key inclusion criteria: cohort 1: dupilumab-exposed cohort * pregnant women * exposure to dupilumab for the treatment of the approved indications of atopic dermatitis (ad) or asthma, for any number of days, at any dose, and at any time from the first day of the lmp up to and including the end of pregnancy. cohort 2: disease-matched comparison cohort (comparison group 1) * pregnant women * diagnosed with a dupilumab-approved indications of moderate-to-severe ad without asthma or moderate-to-severe asthma; frequency matched to the exposed group by disease indication, with the indication and severity validated by medical records when possible. * no exposure to dupilumab any time in the current pregnancy or within 10 weeks of the first day of the lmp and may or may not have taken another medication for their disease in the current pregnancy. cohort 3: healthy comparison cohort (comparison group 2): * pregnant women key exclusion criteria: cohort 1: dupilumab-exposed cohort * women who have first contact with the project after prenatal diagnosis of any major structural defect * women who have used dupilumab for an indication other than asthma or ad cohort 2: disease-matched comparison cohort (comparison group 1): * women who have first contact with the project after prenatal diagnosis of any major structural defect * exposure to dupilumab within 10 weeks of lmp or anytime during the current pregnancy cohort 3: non-diseased comparison cohort (comparison group 2): * exposure to dupilumab within 10 weeks prior to the first day of the lmp * women who have a diagnosis of any dupilumab approved indication * women who have first contact with the project after prenatal diagnosis of any major structural defect note: other protocol defined inclusion/exclusion criteria apply
treatment of skeletal class iii malocclusion using orthodontic removable traction appliance

Conditions: Class III Malocclusion

Summary: this experimental study aims to evaluate the efficiency of the orthodontic removable traction appliance in the treatment of skeletal class iii malocclusion. the study sample will consist of 44 patients with skeletal class iii malocclusion. the sample will be allocated randomly into two groups: experimental group and control group. the dentoskeletal changes will be assessed by using lateral cephalometric radiographs before treatment and after obtaining 3mm positive overjet.

treatment of class iii malocclusion is a major challenge in orthodontic contemporary practice, several appliance have suggested for the treatment of class iii malocclusion, such as the facial mask and chin cup. despite of the efficiency of this extraoral appliance, its external appearance and its big size reduce patients' cooperation which decrease its clinical effects. another class iii treatment modality is the orthodontic removable traction appliance (orta). it is a removable appliance that can be used in conjunction with rapid palatal expansion or fixed appliances, it was developed in the 1980's by dr. david musich who developed this appliance in order to overcome issues of compliance that dr. musich experienced with use of the protraction facemask. there is only one study that evaluated this appliance which is a retrospective study compared the treatment effects of the orta and protraction facemask in treatment of class iii malocclusions. however, this study has a lot of limitations which made it difficult to accurately evaluate the efficiency of this device. the aim of this study is studying the dentoskeletal changes that result from treatment by this device, by comparing them to the changes in matched untreated group,by studying the cephalometric x-rays.

Eligibility criteria:
inclusion criteria: * patients in early mixed dentation (8-10 years old). * skeletal class iii caused by maxillary deficiency with or without mandibular prognathism judged clinically and confirmed radiographically(anb≤1). * anterior crossbite on two teeth or more or an edge-to-edge bite. * normal inclination of the lower incisors with the mandibular plane. exclusion criteria: * poor oral hygiene. * previous orthodontic treatment. * patients with syndromes, clefts, or craniofacial abnormalities. * severe skeletal class iii primarily resulting from mandibular prognathism (anb less than - 4) * patients with facial asymmetry. * patients with vertical growth pattern.

Keywords: class iii treatment orthodontic removable traction appliance rct